|29th May 2020||Tina Gullotta||6,000||Open or private purchase||$0.33||$1,989.00|
|2nd December 2019||Capital Iv, Lp Aisling||689,655||Grant/award etc.||$1.45||$999,999.75|
|29th November 2019||William P. Quinn||6,000||Open or private purchase||$0.37||$2,193.00|
|15th July 2019||Capital Iv, Lp Aisling||2,500,000||Open or private purchase||$0.60||$1,500,000.00|
|31st May 2019||William P. Quinn||6,000||Open or private purchase||$0.65||$3,876.60|
|11th April 2019||Capital Iv, Lp Aisling||428,571||Grant/award etc.||$3.50||$1,499,998.50|
|28th February 2019||William P. Quinn||63,697||Grant/award etc.||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers.